Compare MYO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | XBIT |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 69.8M |
| IPO Year | 2017 | 2015 |
| Metric | MYO | XBIT |
|---|---|---|
| Price | $1.23 | $1.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.64 | N/A |
| AVG Volume (30 Days) | ★ 247.3K | 53.2K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $11.43 | N/A |
| Revenue Next Year | $12.29 | $30.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.61 | $1.91 |
| 52 Week High | $1.89 | $3.44 |
| Indicator | MYO | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 25.20 |
| Support Level | $1.18 | N/A |
| Resistance Level | $1.75 | $2.42 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 6.67 | 10.64 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.